Efalizumab therapy for psoriasis in patients with inadequate responses to etanercept.
Efalizumab is a recombinant humanized monoclonal antibody approved for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis. We present six cases of favorable response to efalizumab therapy in patients with psoriasis who demonstrated inadequate response or who were non-responders to treatment with etanercept, a tumor necrosis factor-alpha-binding fusion protein. The subsequent response of these patients suggests that efalizumab may be a viable treatment option for patients with psoriasis who respond poorly to etanercept.
Kramer
Jesse M
JM
Dermatology Division, Mercy Medical Group, Sacramento, California, USA. Jesse.kramer001@chw.edu
Turner
James E
JE
D000328:Adult; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012720:Severity of Illness Index
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept; C472181:efalizumab